• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

    3/21/24 4:05:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email

    BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.

    Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, April 1 at 9:00 AM ET to review results.

    Conference Details:

    Conference Date: Monday, April 1, 2024 - 9:00 AM ET

    Conference dial-in: 877-407-6184

    International dial-in: 201-389-0877

    Conference Call Name: Xtant Medical Q4 2023 Financial Results

    Webcast Registration: Click Here

    Following the live call, a replay will be available on the Company's website, www.xtantmedical.com, under "Investor Info."

    About Xtant Medical Holdings, Inc.

    Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

    The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

    Investor Relations Contact

    David Carey

    Lazar FINN Partners

    Ph: 212-867-1762

    Email: [email protected]



    Primary Logo

    Get the next $XTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Xtant Medical with a new price target

      BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

      12/5/23 8:12:02 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Nantahala Capital Management, Llc claimed ownership of 68,394,000 shares (SEC Form 3)

      3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/17/25 4:31:14 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $30,708,129 worth of shares (73,114,592 units at $0.42) (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/14/25 7:14:36 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Operations Officer Schallenberger Mark A. was granted 173,469 shares, increasing direct ownership by 85% to 378,613 units (SEC Form 4)

      4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      1/17/25 4:29:24 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care